PRECISIONPanc – development of a targeted panel for personalised medicine in pancreatic cancer
Published: 12 January 2018
The cancer workstrand for the MRC Pathology Node has been working on developing an assay that is GCLP approved and of interest to industry. We have focussed this on defining actionable events in pancreatic cancer and other cancer types.
The cancer workstrand for the MRC Pathology Node has been working on developing an assay that is GCLP approved and of interest to industry. We have focussed this on defining actionable events in pancreatic cancer and other cancer types.
The assay is a capture next generation sequencing assay specifically designed to overcome the challenges of formalin fixation and low cellularity. This assay called the PRECISION-Panc Engineers Diagnostic will form the basis of patient selection in recruitment and assessment in the PRECISION-Panc platform for therapeutic development.
In addition, we have had significant interest from industry with regard to applying this diagnostic, particularly in pancreatic cancer and in some instances other cancer types. We are currently in negotiations in securing those contracts. We aim to continue developing further iterations of this assay in order to extend it into other aspects that go beyond the point mutations in single genes including RNA-seq for patient selection for immunotherapy.
Click here to find out more about PRECISIONPanc
First published: 12 January 2018